Results 41 to 50 of about 195,691 (306)

Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage

Рациональная фармакотерапия в кардиологии, 2021
Intracerebral hemorrhage (ICH) is severe and fatal complication of anticoagulant therapy with an incidence 0.3-0.7% per year. For patients with atrial fibrillation (AF) anticoagulants are administered for decreasing risk of stroke and systemic embolism ...
A. S. Gerasimenko, V. S. Gorbatenko, O. V. Shatalova, V. I. Petrov   +3 more
doaj   +1 more source

Embolic strokes of undetermined source: prevalence and patient features in the ESUS Global Registry [PDF]

, 2016
Background: Recent evidence supports that most non-lacunar cryptogenic strokes are embolic. Accordingly, these strokes have been designated as embolic strokes of undetermined source (ESUS).
Ameriso, Sebastian F, Arauz, Antonio, Berkowitz, Scott D, Bosch, Jackie, Brouns, Raf, Connolly, Stuart J, Coutinho, Jonathan, Cunha, Luis, Gagliardi, Rubens J, Giruparajah, Mohana, Hankey, Graeme J, Hart, Robert G, Kasner, Scott E, Kitagawa, Kazuo, Lavallee, Philippa, Mattina, Katie R, Muir, Keith, O\u2019Donnell, Martin J, Perera, Kanjana S, Pieroni, Alessio, Shamalov, Nikolay, Swaminathan, Balakumar, Vanassche, Thomas, Vastagh, Ildiko, Vermehren, Philipp, Wang, Yongjun, Yoon, Byung-Woo, Yperzeele, Laetitia   +27 more
core   +10 more sources

Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atrial Fibrillation) [PDF]

, 2016
Introduction: Atrial fibrillation is an independent risk factor of thromboembolism. Women with atrial fibrillation are at a higher overall risk for stroke compared to men with atrial fibrillation. The aim of this study was to evaluate for sex differences
Abdul-Rahim, Azmil, Acciarresi, Monica, Ageno, Walter, Agnelli, Giancarlo, Akhtar, Naveed, Alberti, Andrea, Antonenko, Kateryna, Baldi, Antonio, Barlinn, Kristian, Baronello, Mario M., Becattini, Cecilia, Bodechtel, Ulf, Bono, Giorgio, Bovi, Paolo, Carletti, Monica, Carolei, Antonio, Caso, Valeria, Chiti, Alberto, Consoli, Domenico, Cordier, Maria, Corea, Francesco, Csiba, Laszló, De Lodovici, Maria Luisa, Del Sette, Massimo, Deleu, Dirk, Denti, Licia, Doronin, Boris, D’Amore, Cataldo, D’Anna, Antonio, Falocci, Nicola, Galati, Franco, Gerber, Johannes, Gialdini, Gino, Guideri, Francesca, Ibrahim, Faisal, Imberti, Davide, Kepplinger, Jessica, Lees, Kennedy R., Lorenzini, Gianni, Marcheselli, Simona, Martini, Giuseppe, Masotti, Luca, Melikyan, Gayane, Michel, Patrik, Monaco, Serena, Mosconi, Maria G., Orlandi, Giovanni, Paciaroni, Maurizio, Padovani, Alessandro, Pallesen, Lars-Peder, Papageorgiou, Sokratis G., Pezzini, Alessandro, Pieroni, Alessio, Poli, Loris, Putaala, Jukka, Remillard, Suzette, Rigatelli, Alberto, Rueckert, Christina, Sacco, Simona, Scoditti, Umberto, Sohn, Sung-Il, Szabó6, Lilla, Tassi, Rossana, Tassinari, Tiziana, Tatlisumak, Turgut, Tiseo, Cindy, Toni, Danilo, Tsivgoulis, Georgios, Vadik, Kostantinos, Vanacker, Peter, Venti, Michele, Volodina, Vera, Zabzuni, Dorjan   +72 more
core   +1 more source

More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]

, 2018
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M, Hirsh J, Ibanez B, Mega JL, Park KW, Suh JW, Valgimigli M   +6 more
core   +3 more sources

Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis? [PDF]

, 2019
Porto sinusoidal vascular liver disease (PSVD) and portal vein thrombosis (PVT) are distinct vascular liver diseases characterized, respectively, by an intrahepatic and a prehepatic obstacle to the flow in the liver portal system. PVT may also occur as a
D'Amati, G., Gioia, S., Nardelli, S., Ridola, L., Riggio, O.   +4 more
core   +1 more source

D-dimer trends predict recurrent stroke in patients with cancer-related hypercoagulability

Cerebrovascular Diseases Extra, 2023
Introduction: In patients with cancer-associated hypercoagulability (CAH)-related stroke, D-dimer trends after anticoagulant therapy may offer a biomarker of treatment efficacy.
Jun Fujinami, Yoshinari Nagakane, Kei Fujikawa, Shohei Murata, Keiko Maezono, Tomoyuki Ohara, Toshiki Mizuno   +6 more
doaj   +1 more source

How to define the relative contraindications to oral anticoagulant therapy

Monaldi Archives for Chest Disease, 2017
There is currently a lack of consensus on which anticoagulant therapy contraindications should be considered “absolute” and which should be considered “relative”. Guidelines do not clearly identify absolute and relative contraindications to anticoagulant
Roberto F.E. Pedretti
doaj   +1 more source

Cerebrovascular complications and infective endocarditis. impact of available evidence on clinical outcome [PDF]

, 2018
Infective endocarditis (IE) is a life-threatening disease. Its epidemiological profile has substantially changed in recent years although 1-year mortality is still high.
De Bellis, Antonio, D’Abramo, Mizar, Frati, Giacomo, Greco, Ernesto, Iaccarino, Alessandra, Mestres, Carlos-A., Saade, Wael, Schirone, Leonardo, Sciarretta, Sebastiano   +8 more
core   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

SELECTING AN OPTIMAL LONG-TERM ANTICOAGULANT THERAPY FOR A PATIENT WITH ATRIAL FIBRILLATION AND RECURRENT MINOR HEMORRHAGE. CLINICAL FOLLOW-UP

Атеротромбоз, 2017
For patients with atrial fibrillation, long-term oral anticoagulant therapy reduces the risk of ischemic stroke and systemic embolism, while increasing the risk of hemorrhagic complications.
E. S. Kropacheva, E. P. Panchenko
doaj   +1 more source